Alzheimer's Disease: Explore beta-amyloid, tau proteins, and neuroinflammatory markers like TNF-α as indicators of Alzheimer's progression

Authors

  • Sharara Fadhil Abbood Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala, Karbala, Iraq
  • Taha H. Alnasrawi College of Veterinary, University of Kerbala, Karbala, Iraq
  • Zahraa Talib Mashlool Department of chemistry, College of science, University of Kerbala, Karbala, Iraq

DOI:

https://doi.org/10.47577/technium.v26i.12382

Keywords:

Alzheimer’s disease, beta-amyloid, tau protein, TNF-α, neuroinflammation

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects millions globally, leading to cognitive decline and, ultimately, death. Key pathogenic hallmarks of AD include the accumulation of beta-amyloid plaques and tau protein tangles in the brain, accompanied by neuroinflammatory responses. The aim of this study is to analyze the serum levels of neuroinflammatory markers, particularly TNF-α, along with beta-amyloid and tau proteins, to better understand their roles in Alzheimer's progression. A cohort of 100 AD patients, aged 60 to 85, was compared with a control group of 50 healthy individuals of similar age. Levels of TNF-α, beta-amyloid, and tau proteins were measured using an enzyme-linked immunosorbent assay (ELISA). Findings revealed significantly higher levels of TNF-α, beta-amyloid, and tau in the AD group compared to the control group, suggesting a correlation between inflammatory processes and protein aggregation in the progression of Alzheimer's. This study highlights the potential of these biomarkers as diagnostic tools for early detection and as targets for therapeutic intervention to slow cognitive decline in AD patients.

References

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297(5580):353-6.

Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62.

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.

Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: The story so far. Nat Rev Neurol. 2016;12(1):15-27.

Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59.

Hampel H, Hardy J, Blennow K, et al. The amyloid-beta pathway in Alzheimer's disease. Mol Psychiatry. 2018;23(5):677-89.

Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat Immunol. 2015;16(3):229-36.

McAlpine FE, Tansey MG, Kohman RA. Inflammation and cytokine production in Alzheimer's disease: The role of TNF-α as a pathogenic factor. Prog Neurobiol. 2009;87(4):233-44.

Decourt B, Sabbagh MN, Bales K. Exploiting the pi3k/Akt/mTOR pathway for the treatment of Alzheimer's disease. J Neuroimmunol. 2017;305:88-94.

Mhatre M, Nguyen A, Kashani S, et al. TNF-alpha and TNF-alpha receptor-1 in Alzheimer's disease. J Alzheimers Dis. 2004;6(3):319-29.

Nelson PT, Head E, Schmitt FA, et al. Alzheimer's disease is not “brain aging”: Neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2012;123(5):667-74.

Abyadeh M, Meyfour A, Gupta V, Zabet Moghaddam M, Fitzhenry MJ, Shahbazian S, Hosseini Salekdeh G, Mirzaei M. Recent advances of functional proteomics in gastrointestinal cancers—A path towards the identification of candidate diagnostic prognostic and therapeutic molecular biomarkers. Int J Mol Sci. 2020;21:8532.

Abyadeh M, Gupta V, Chitranshi N, Gupta V, Wu Y, Saks D, Wander Wall R, Fitzhenry MJ, Basavarajappa D, You Y. Mitochondrial dysfunction in Alzheimer's disease—a proteomics perspective. Expert Rev Proteomics. 2021;18:295-304.

Abyadeh M, Tofigh N, Hosseinian S, Hasan M, Amirkhani A, Fitzhenry MJ, Gupta V, Chitranshi N, Salekdeh GH, Haynes PA. Key genes and biochemical networks in various brain regions affected in Alzheimer's disease. Cells. 2022;11:987.

Abyadeh M, Yadav V, Kaya A. Common molecular signatures between coronavirus infection and Alzheimer's disease reveal targets for drug development. bioRxiv. 2023;doi:10.1101/2023.06.14.544970.

Abyadeh M, Gupta V, Paulo JA, Sheriff S, Shadfar S, Fitzhenry M, Amirkhani A, Gupta V, Salekdeh GH, Haynes PA, Graham SL, Mirzaei M. Apolipoprotein ε in brain and retinal neurodegenerative diseases. Aging Dis. 2023;14:1311-30.

Acosta SA, Tajiri N, Sanberg PR, Kaneko Y, Borlongan CV. Increased amyloid precursor protein and tau expression manifests as key secondary cell death in chronic traumatic brain injury. J Cell Physiol. 2017;232:665-77.

Albayram O, Kondo A, Mannix R, Smith C, Tsai CY, Li C, Herbert MK, Qiu J, Monuteaux M, Driver J. Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. Nat Commun. 2017;8:1000.

Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present and predictions for the future. Cureus. 2020;12:e11686.

Anderson J, Hampton D, Patani R, Pryce G, Crowther R, Reynolds R, Franklin R, Giovannoni G, Compston D, Baker D. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain. 2008;131:1736-48.

Andriessen TM, Jacobs B, Vos PE. Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J Cell Mol Med. 2010;14:2381-92.

Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, Sherman SL, Reeves RH. Down syndrome. Nat Rev Dis Primers. 2020;6:9.

Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602-11.

Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661-6.

Downloads

Published

2025-01-06

How to Cite

Abbood, S. F., Alnasrawi, T. H., & Mashlool, Z. T. (2025). Alzheimer’s Disease: Explore beta-amyloid, tau proteins, and neuroinflammatory markers like TNF-α as indicators of Alzheimer’s progression. Technium: Romanian Journal of Applied Sciences and Technology, 26, 64–75. https://doi.org/10.47577/technium.v26i.12382